In August 2012, our lawyers represented Novartis Bioventures in the issuance of Series A1 Preferred Stock of Aerpio Therapeutics, Inc. Aerpio Therapeutics, Inc., based in Cincinnati, Ohio, is a clinical-stage biopharmaceutical company that engages in the development of therapies for vascular diseases. Novartis Bioventures, is a venture fund based in Cambridge, Massachusetts.
Posted on August 28, 2012